AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 39580437
Drug: Empirical antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empirical antibiotic therapy
Trial: 39580437
Drug: Adherence to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adherence to guidelines for empirical antibiotic therapy
Trial: 39580437
Drug: Adherence to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adherence to guidelines for therapy duration
Trial: 39580437
Drug: C-reactive protein
RxNorm normalized name: C-reactive protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C-reactive protein (CRP) level exceeding 100 mg/L
Trial: 39580437
Drug: Planned post-discharge
RxNorm normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Planned post-discharge treatment
Trial: 39580437
Drug: Temporal trends
RxNorm normalized name: Sus scrofa temporal lobe preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Temporal trends in adherence to treatment duration guidelines
Trial: 39580793
Drug: Hydroxyurea and
RxNorm normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxyurea and chronic transfusion therapy (HAT)
Trial: 39581197
Drug: Tislelizumab 200
RxNorm normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tislelizumab 200 mg plus platinum-based doublet chemotherapy followed by adjuvant tislelizumab 400 mg every 6 weeks.
Trial: 39581197
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus platinum-based doublet chemotherapy followed by placebo every 6 weeks.
Trial: 39581202
Drug: Mirikizumab 900
RxNorm normalized name: Mirikizumab
DrugBank: Mirikizumab (DB14910)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mirikizumab 900 mg IV at weeks 0, 4, and 8, then 300 mg SC every 4 weeks from weeks 12 to 52
Trial: 39581380
Drug: Lorlatinib 100
RxNorm normalized name: lorlatinib 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lorlatinib 100 mg orally once daily in continuous 21-day cycles
Trial: 39581631
Drug: Cenerimod 2
RxNorm normalized name: Cenerimod
DrugBank: Cenerimod (DB12705)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cenerimod 2 mg
Trial: 39581729
Drug: 1L therapy
RxNorm normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1L therapy (first systemic treatment for A/R EC with or without radiotherapy)
Trial: 39581739
Drug: Mobile health
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mobile health (mHealth) and graphic medicine (comic) programme for mental health alongside HIVST
Trial: 39581739
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of HIVST, a livelihoods programme, and mHealth mental health programme
Trial: 39581887
Drug: 4 implants
RxNorm normalized name: Drug Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 implants (4-I)
Trial: 39581887
Drug: 6 implants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 implants (6-I)
Trial: 39581957
Drug: Intravenous omadacycline
RxNorm normalized name: omadacycline
DrugBank: Omadacycline (DB12455)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous omadacycline 100 mg over 0.5 h
Trial: 39581957
Drug: Oral omadacycline
RxNorm normalized name: omadacycline
DrugBank: Omadacycline (DB12455)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral omadacycline 300 mg
Trial: 39582029
Drug: 750,000 IU
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 750,000 IU of vitamin D3 via enteral or oral route
Trial: 39582048
Drug: Suspended/stopped anti-cancer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suspended/stopped anti-cancer treatment
Trial: 39583219
Drug: Systemic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic therapy candidates identified based on IPC criteria
Trial: 39583219
Drug: Systemic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic therapy candidates with BSA >10%
Trial: 39583219
Drug: Systemic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic therapy candidates with history of psoriasis affecting special areas
Trial: 39583219
Drug: Systemic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic therapy candidates with prior use of topical therapy
Trial: 39583219
Drug: Systemic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic therapy candidates with PASI scores ≤12
Trial: 39583952
Drug: Ipilimumab (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ipilimumab (1 mg/kg IV every 6 weeks) plus Nivolumab (240 mg IV every 2 weeks)
Trial: 39583953
Drug: Novel hormonal
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Novel hormonal therapies
Trial: 39584139
Drug: Prucalopride 2
RxNorm normalized name: prucalopride 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prucalopride 2 mg enterally once daily for 7 days
Trial: 39584139
Drug: Metoclopramide 10
RxNorm normalized name: metoclopramide 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide 10 mg intravenously every 6-8 hours for 7 days
Trial: 39584380
Drug: C10 monoclonal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C10 monoclonal antibody (mAb) targeting SARS-CoV-2
Trial: 39584380
Drug: C10-based Chimeric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C10-based Chimeric Antigen Receptor (CAR)-T cells
Trial: 39584557
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy (IC) followed by chemoradiotherapy (CRT)
Trial: 39584789
Drug: All-trans retinoic
RxNorm normalized name: all trans Retinoic acid
DrugBank: Tretinoin (DB00755)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All-trans retinoic acid (ATRA) 45 mg/m2, arsenic trioxide (ATO), and gemtuzumab ozogamicin (GO)
Trial: 39585339
Drug: Nivolumab +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab + BMS986205 (IDO-inhibitor)
Trial: 39585605
Drug: High-realistic clinical
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-realistic clinical simulation during drug administration
Trial: 39585936
Drug: Cilostazol (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cilostazol (50 or 100 mg, twice per day) added to other antiplatelets
Trial: 39586309
Drug: Radioiodine group
RxNorm normalized name: Radioiodine
DrugBank: Iodide I-131 (DB09293)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radioiodine group (1·1 GBq-30 mCi after recombinant human thyrotropin-stimulating hormone)
Trial: 39586616
Drug: Infliximab (IFX)
RxNorm normalized name: Infliximab
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Infliximab (IFX) plus azathioprine (AZA) with a 7-day steroid tapering scheme
Trial: 39586616
Drug: Azathioprine (AZA)
RxNorm normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azathioprine (AZA) with conventional standardised steroid tapering regimen
Trial: 39587504
Drug: SSRIs with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SSRIs with Control treatment
Trial: 39587622
Drug: High-concentration platelet-rich
RxNorm normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High-concentration platelet-rich plasma (PRP) injection
Trial: 39587799
Drug: High protein
RxNorm normalized name: Vital High Protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High protein breakfast (34 g protein)
Trial: 39587796
Drug: Tegoprazan (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tegoprazan (50 mg)
Trial: 39587825
Drug: Extended DAPT
RxNorm normalized name: DAPT
DrugBank: Diaminopropanol tetraacetic acid (DB12362)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended DAPT (75 mg clopidogrel plus 75-150 mg aspirin daily)
Trial: 39587825
Drug: Monotherapy (75-150 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monotherapy (75-150 mg aspirin daily)
Trial: 39587915
Drug: Acupuncture treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture treatment (twice a week for 4 weeks)
Trial: 39587931
Drug: PVRV-NG2 (three-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PVRV-NG2 (three-dose regimen)
Trial: 39587931
Drug: PVRV-NG2 (two-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PVRV-NG2 (two-dose regimen)
Trial: 39587931
Drug: HDCV (three-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HDCV (three-dose regimen)
Trial: 39587931
Drug: PVRV (three-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PVRV (three-dose regimen)
Trial: 39588131
Drug: Antiresorptive therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiresorptive therapy (ibandronate)
Trial: 39588987
Drug: ADS051 1,500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ADS051 1,500 mg
Trial: 39588987
Drug: All dose
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All dose groups of ADS051
Trial: 39589133
Drug: BIC 75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BIC 75 mg + LEN 25 mg (n = 51)
Trial: 39589133
Drug: BIC 75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BIC 75 mg + LEN 50 mg (n = 52)
Trial: 39589133
Drug: BIC 75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BIC 75 mg + LEN 25 mg
Trial: 39589133
Drug: BIC 75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BIC 75 mg + LEN 50 mg
Trial: 39589133
Drug: BIC +
RxNorm normalized name: Bictegravir plus emtricitabine and tenofovir alafenamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BIC + LEN (both dosing regimens)
Trial: 39589314
Drug: Contrast-Enhanced Ultrasound
RxNorm normalized name: Contrased
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contrast-Enhanced Ultrasound (CEUS) with 2 mL sulfur hexafluoride lipid-type A microspheres (Lumason) per lesion
Trial: 39589314
Drug: Hepatobiliary agent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatobiliary agent MRI (HBA-MRI)
Trial: 39589314
Drug: Hepatobiliary agent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatobiliary agent MRI (HBA-MRI) for lesions ≥ 2 cm
Trial: 39589664
Drug: Alendronate solution
RxNorm normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alendronate solution (ALN-S)
Trial: 39589664
Drug: Alendronate tablet
RxNorm normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alendronate tablet (ALN-T)
Trial: 39589666
Drug: Generic nab-paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Generic nab-paclitaxel monotherapy
Trial: 39589666
Drug: Generic nab-paclitaxel-based
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Generic nab-paclitaxel-based combination therapy
Trial: 39589666
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with ≥ 4 treatment cycles
Trial: 39589690
Drug: Tarlatamab (0.003,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tarlatamab (0.003, 0.01, 0.03, 0.1, 0.3, 1, 3, 10, 30, and 100 mg) administered every 2 weeks (Q2W) with a step dose regimen starting at 3 mg; infused over 1 hour.
Trial: 39589721
Drug: Nurse-delivered brief
RxNorm normalized name: DELIVER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nurse-delivered brief behavioral treatment for insomnia (BBTI)
Trial: 39589730
Drug: Immunosuppressive therapies
RxNorm normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunosuppressive therapies
Trial: 39590165
Drug: Lenalidomide and
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lenalidomide and Dexamethasone (Len/Dex) followed by Donor Lymphocyte Infusions (DLIs)
Trial: 39591190
Drug: Prime-2-CoV_Beta vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prime-2-CoV_Beta vaccine
Trial: 39591365
Drug: Autologous adipose-derived
RxNorm normalized name: Autologous adipose-derived stromal vascular fraction cells
DrugBank: Autologous adipose-derived stromal vascular fraction cells (DB18679)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous adipose-derived regenerative cells (ADRCs) (4.20×10^7 ± 1.75×10^7 cells) and 30-cc lipotransfer
Trial: 39591420
Drug: Medication Coordinator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication Coordinator intervention with medication review and suggested amendments documented in electronic discharge letter sent to GP
Trial: 39591420
Drug: Medication Coordinator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication Coordinator intervention
Trial: 39591551
Drug: Lenvatinib 20
RxNorm normalized name: LENVATINIB 20MG DAILY DOSE PACK,10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lenvatinib 20 mg once daily plus Pembrolizumab 200 mg once every 3 weeks
Trial: 39591551
Drug: Chemotherapy (Paclitaxel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (Paclitaxel 175 mg/m2)
Trial: 39592468
Drug: Synbiotic supplementation
RxNorm normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Synbiotic supplementation (including L. rhamnosus DSM 32550, Humiome® L. plantarum DSM 34532, B. lactis DSM 32269, B. longum DSM 32946, fructooligosaccharides and zinc)
Trial: 39592547
Drug: FIL200 (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FIL200 (200 mg once daily)
Trial: 39592547
Drug: FIL100 (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FIL100 (100 mg once daily)
Trial: 39592547
Drug: Adalimumab (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adalimumab (40 mg biweekly)
Trial: 39592626
Drug: Allergen-specific immunotherapy
RxNorm normalized name: Pacific halibut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allergen-specific immunotherapy (AIT)
Trial: 39592888
Drug: BAT4406F (escalated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BAT4406F (escalated doses ranging from 20 to 750 mg)
Trial: 39593101
Drug: Robotics-assisted therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Robotics-assisted therapy (RAT) at home for 30 consecutive days after 2 therapist-supervised clinic onboarding sessions.
Trial: 39593537
Drug: Cervical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cervical therapy protocol + active cervical postural treatment for 4 weeks
Trial: 39593537
Drug: Active cervical
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active cervical postural treatment for 4 weeks
Trial: 39593541
Drug: Reformer Pilates
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reformer Pilates exercise (6-week program, 45 min/twice per week)
Trial: 39594812
Drug: Roflumilast in
RxNorm normalized name: Product containing roflumilast in oral dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Roflumilast in combination with R-CHOP (Ro+R-CHOP)
Trial: 39596792
Drug: Inhaled Colistin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled Colistin via nebulizer type A
Trial: 39596792
Drug: Inhaled Colistin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled Colistin via nebulizer type B
Trial: 39599585
Drug: Calcifediol 75
RxNorm normalized name: Calcifediol
DrugBank: Calcifediol (DB00146)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcifediol 75 µg
Trial: 39599585
Drug: Calcifediol 100
RxNorm normalized name: Calcifediol
DrugBank: Calcifediol (DB00146)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcifediol 100 µg
Trial: 39599686
Drug: Carnosine supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carnosine supplementation (2 g/day for 14 weeks)
Trial: 39599746
Drug: Omega-3 fatty
RxNorm normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3 fatty acids (ω3) supplementation (300 mg capsules, 2 daily for 9 weeks)
Trial: 39599746
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D (VitD) supplementation (50,000 IU tablet, 1 weekly for 9 weeks)
Trial: 39599964
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (conventional swallowing therapy without videos)
Trial: 39601122
Drug: Pulsed Field
RxNorm normalized name: Field mushroom
DrugBank: Field mushroom (DB15605)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulsed Field Ablation (PFA) as first-line therapy
Trial: 39601122
Drug: Pulsed Field
RxNorm normalized name: Field mushroom
DrugBank: Field mushroom (DB15605)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulsed Field Ablation (PFA) after prior class I/III AAD therapy
Trial: 39601214
Drug: Electrical shock
RxNorm normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Electrical shock treatment (5 milliamps)
Trial: 39601265
Drug: Clesrovimab (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clesrovimab (100 mg for full-term, 20, 50, 75, or 100 mg for preterm)
Trial: 39601271
Drug: Center M
RxNorm normalized name: clean air center MISCELL EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Center M intervention (4 one-hour weekly group telehealth sessions)
Trial: 39601296
Drug: Sub-ulcer foam
RxNorm normalized name: DAB(SUB 389)IL2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sub-ulcer foam sclerotherapy and compression therapy
Trial: 39601296
Drug: Compression therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compression therapy only
Trial: 39601743
Drug: Clopidogrel monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel monotherapy for normal, rapid, or ultrarapid CYP2C19 metabolizers (n=69)
Trial: 39601743
Drug: Prasugrel or
RxNorm normalized name: prasugrel Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prasugrel or ticagrelor monotherapy for loss-of-function allele carriers (n=29)
Trial: 39601743
Drug: Dual antiplatelet
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual antiplatelet therapy (clopidogrel and aspirin) for all patients initially
Trial: 39601933
Drug: PharmaCAP intervention
RxNorm normalized name: Pharmasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PharmaCAP intervention (clinical pharmacist-led medication review, pain assessment, education, and counseling)
Trial: 39601981
Drug: 2 h/12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 h/12 h intravenous infusion of Cyclosporin A (CsA)
Trial: 39601981
Drug: 22 h
RxNorm normalized name: C18-22 Hydroxyalkyl Hydroxypropyl Guar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 22 h continuous infusion of Cyclosporin A (CsA)
Trial: 39602139
Drug: Nemolizumab (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nemolizumab (30 mg or 60 mg depending on baseline weight) administered every 4 weeks for 24 weeks
Trial: 39602341
Drug: CAR T-cell
RxNorm normalized name: CD123-CD33cCAR T-cells
DrugBank: ICG-136 (DB17343)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAR T-cell therapy (ARI0002h; academic BCMA-targeted CAR T-cell therapy)
Trial: 39602441
Drug: Peer-assisted telemedicine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peer-assisted telemedicine HCV treatment (TeleHCV)
Trial: 39602479
Drug: MIC spray
RxNorm normalized name: Ophthalmic Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MIC spray mixed with 6 mg aspirin + placebo tablet (Treatment 1)
Trial: 39602479
Drug: MIC spray
RxNorm normalized name: Ophthalmic Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MIC spray mixed with 6 mg wintergreen oil + placebo tablet (Treatment 2)
Trial: 39602479
Drug: MIC spray
RxNorm normalized name: Ophthalmic Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MIC spray mixed with 6 mg wintergreen oil + 325 mg aspirin tablet (Treatment 3)
Trial: 39602624
Drug: Daily oral
RxNorm normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily oral emtricitabine-tenofovir disoproxil fumarate (F/TDF)
Trial: 39602624
Drug: Subcutaneous lenacapavir
RxNorm normalized name: Lenacapavir
DrugBank: Lenacapavir (DB15673)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous lenacapavir
Trial: 39602629
Drug: 1 primary
RxNorm normalized name: Sodium primary phosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 primary dose and 1 booster dose of PCV10 (1p+1)
Trial: 39602629
Drug: 2 primary
RxNorm normalized name: Sodium primary phosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 primary doses and 1 booster dose of PCV10 (2p+1)
Trial: 39602629
Drug: 3 primary
RxNorm normalized name: Sodium primary phosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 primary doses of PCV10 (3p+0)
Trial: 39602629
Drug: 0 primary
RxNorm normalized name: Sodium primary phosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 primary doses and 1 booster dose of PCV10 (0p+1)